Secukinumab is a fully human monoclonal antibody directed against interleukin-17A. The SHIKARI® Secukinumab portfolio supports two distinct research questions: quantitative measurement of secukinumab concentration and qualitative detection of specific anti-secukinumab antibodies.
Secukinumab has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗
Secukinumab is a fully human IgG1κ monoclonal antibody that selectively binds and neutralises interleukin-17A. Source ↗
EMA-authorised uses include plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, selected juvenile idiopathic arthritis categories and hidradenitis suppurativa. EMA source ↗
FDA pharmacokinetic data provide dose-dependent steady-state trough references for every-four-week dosing:
Regulatory exposure values are regimen- and population-specific and are not therapeutic targets. Values vary with dose, timing, formulation and study population. This page is for RUO product information and does not provide clinical guidance.
Enzyme immunoassay for the quantitative determination of secukinumab in human serum and plasma, developed for concentration measurement between the Cmin and Cmax range.
Enzyme immunoassay for the qualitative determination of specific antibodies to secukinumab in human serum and plasma. No standard curve is shown because this assay reports a qualitative positive/negative result.
| Kit Name | Catalog Code | Type | Analyte | ELISA Format | Tests | Storage |
|---|---|---|---|---|---|---|
| SHIKARI® Q-SEC | SEC-FD-VER | Drug-Level Kit | Secukinumab | ELISA | 96 | 2–8°C |
| SHIKARI® S-ATSEC | SEC-QLS-VER | Qualitative ADA Kit | Specific anti-secukinumab antibodies | ELISA | 96 | 2–8°C |
* Store at +4°C and refer to the current protocol supplied with the kit. Specifications were verified against the official product records.
Choose the assay by analyte and measurement mode rather than treating drug concentration and binding antibodies as equivalent.
Matrix Biotek can help identify the appropriate Secukinumab assay and prepare regional quotation and delivery information. SHIKARI® products are developed and manufactured in Ankara and supported through our European headquarters in Barcelona.